CC
SNDX icon

Clearline Capital’s Syndax Pharmaceuticals SNDX Stock Holding History

Clearline Capital’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-43,413
Closed -$1.01M – 123
2026
Q1 		$1.01M Hold
43,413
– – 0.05% 96
2025
Q4 		$912K Buy
43,413
+9,236
+27% +$161K 0.05% 92
2025
Q3 		$526K Hold
34,177
– – 0.02% 103
2025
Q2 		$320K Hold
34,177
– – 0.01% 105
2025
Q1 		$420K Hold
34,177
– – 0.03% 109
2024
Q4 		$452K Sell
34,177
-8,018
-19% -$137K 0.06% 92
2024
Q3 		$812K Hold
42,195
– – 0.03% 124
2024
Q2 		$866K Buy
+42,195
New +$883K 0.02% 121

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Clearline Capital's SNDX Position: Q2 2026 in Review

Clearline Capital sold out of Syndax Pharmaceuticals (SNDX) in Q2 2026, closing a stake of 43,413 shares — an estimated $1.01M sold.

Clearline Capital first reported a position in SNDX in Q2 2024 and held it in 8 quarters. The position peaked at $1.01M in Q1 2026. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Clearline Capital reported no remaining Syndax Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Clearline Capital sold 43,413 Syndax Pharmaceuticals shares in Q2 2026, an estimated $1.01M.
  • Clearline Capital first reported a position in Syndax Pharmaceuticals in Q2 2024 and held it in 8 quarters.
  • Clearline Capital's Syndax Pharmaceuticals position peaked at $1.01M in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Clearline Capital's 13F filing for Q2 2026, filed 14 Aug 2026.